Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum CEL-SCI Corp CVM

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck... see more

NYSEAM:CVM - Post Discussion

CEL-SCI Corp > Why CEL-SCI Corporation (CVM) Shares Are Diving | Benzinga
View:
Post by whytestocks on Feb 09, 2024 6:30pm

Why CEL-SCI Corporation (CVM) Shares Are Diving | Benzinga

Breaking News: $CVM Why CEL-SCI Corporation (CVM) Shares Are Diving | BenzingaCEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 13.9% to $2.46 Friday morning after the company priced an offering of 3.875 million sh...CVM - Why CEL-SCI Corporation (CVM) Shares Are Diving | Benzinga
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities